48 research outputs found

    Volumes of viral load specimens collected/received/tested and corresponding median pretest phase and test phase turnaround times.

    No full text
    <p>2(A) National number of specimens collected and referred for viral load testing by month and corresponding monthly median pretest phase turnaround time. 2(B) Number of specimens referred by district and corresponding median pretest phase turnaround time by district. 2(C) National number of specimens received at the laboratory for viral load testing by month and corresponding monthly median test phase turnaround time. 2(D) Number of specimens received per laboratory and corresponding median test phase turnaround time by laboratory. All pretest and test phase turnaround times were calculated using only specimens with valid dates.</p

    Turnaround time definitions and specimens used in turnaround time calculations.

    No full text
    <p>Afferent turnaround time is defined as the number of days elapsed between specimen collection and specimen testing. Two phases are defined within afferent turnaround time: Pretest phase, the number of days elapsed between specimen collection and date of receipt at the laboratory; and Test phase, the number of days elapsed between specimen receipt at the laboratory and the date of testing. Efferent turnaround time, which was not assessed in this study, is defined as the number of days elapsed between the date of testing and the date the result is received by the patient. Of 243,539 viral load specimens tested between 2013 and March 2016: 219,121 specimens had valid dates of both specimen collection and testing and thus were included in calculations of afferent turnaround time, 207,645 specimens had valid dates of both specimen collection and receipt at the laboratory and thus were included in calculations of pretest phase turnaround time, and 214,786 specimens had valid dates of both receipt and testing and thus were included in calculations for test phase turnaround time. Valid dates were defined as those that were present and plausible (e.g., an implausible testing date would be one that fell prior to the specimen collection date).</p

    Predicted prevalence ratios of self-reporting condomless last sex (with any partner) for each of the 14 survey countries by sex.

    No full text
    Predicted prevalence ratios of self-reporting condomless last sex (with any partner) for each of the 14 survey countries by sex.</p

    Predicted prevalence ratios of self-reporting condomless casual partnership for each of the 14 survey countries by sex.

    No full text
    Predicted prevalence ratios of self-reporting condomless casual partnership for each of the 14 survey countries by sex.</p

    Proportion of transmission attributed to PLHIV sub-group by sex across all 14 PHIA surveys (sensitivity analysis using Hill function of transmission and viremia relationship, and assuming the adjusted prevalence ratio of self-reporting HIV high-risk behaviour among untreated PLHIV was half that among PLHIV on ART).

    No full text
    Proportion of transmission attributed to PLHIV sub-group by sex across all 14 PHIA surveys (sensitivity analysis using Hill function of transmission and viremia relationship, and assuming the adjusted prevalence ratio of self-reporting HIV high-risk behaviour among untreated PLHIV was half that among PLHIV on ART).</p

    Proportion of transmission attributed to PLHIV sub-group by sex across all 14 PHIA surveys (sensitivity analysis using Hill function of transmission and viremia relationship, and adjusted prevalence ratio of self-reporting condomless last sex (with any partner) in transmission equation).

    No full text
    Proportion of transmission attributed to PLHIV sub-group by sex across all 14 PHIA surveys (sensitivity analysis using Hill function of transmission and viremia relationship, and adjusted prevalence ratio of self-reporting condomless last sex (with any partner) in transmission equation).</p

    Distribution of plasma HIV RNA and mean log<sub>10</sub> VL among (a) women and (b) men with LLV, non-suppressed VL and those diagnosed but untreated and undiagnosed across 14 PHIA surveys.

    No full text
    Note: unable to reliably estimate distribution due to small number of men diagnosed but untreated in the Ethiopia PHIA survey.</p
    corecore